full comment requir non-u analyst conflict disclosur
pleas click link
tabl turn initi outperform
mix overshadow rule vadadustat
ebitda miss drive share lower concern around ramp center stage
steadi goe
upcom datapoint bridg data
search new plan
newer oper continu improv along strength ss base
takeaway hr investor brief
manag meet highlight far good cobr panama
note road ndr eleph room
takeaway hr investor meet
eps/cfp slight miss pivot scale develop
post-cal lusp submiss focu clinic catalyst
model updat asthma data featur oral present eaaci
manag
price prior day market close estimate unless otherwis note
pictur week volume
 of daili summari
us wrap
solid dropbox
invest activ picked-up improv
overal solid quarter despit stock reaction guidanc re-affirmed expect
adjust ebitda ahead revenu guidanc unchang
post-cal edelweiss get underway implant data expect ye
strategi detail ep re-set execut valuat debat continu
model updat focu usher syndrom data post-rdeb program spin-out
road manag
move annual guidanc signifi strategi shift recur iot servic
balanc still deliv promis
craft unit maintain sector perform
littl new eve approv favor set-up gvoke pdufa
largest increas largest declin
tight market support zinc price
earn recap trend
showcas differenti servic
find research
insight www rbcinsightresearch com global research destin web contact capit market sale
repres access global research site use ipad app research
tabl turn initi outperform
initi coverag templ webster group ltd tpw outperform
rate price target tpw australia largest on-line retail
furnitur homewar attract scalabl model strong revenu growth
strong market posit fragment market on-line penetr
valu aud unless otherwis note
valu usd unless otherwis note
initi tpw australia largest on-line retail furnitur
homewar outperform recommend price
target expect tailwind increas on-line penetr within space
low compar global peer market forecast grow market
share tpw view key revenu driver tpw reach
ebitda profit free cash flow posit current grow
revenu annual
mix overshadow rule vadadustat
report weak auryxia line model though result
overshadow competitor post-clos announc mix
roxadustat data roxa data commun cryptic
surmis trial narrowli miss mace non-inferior endpoint dd-ckd
ndd-ckd view concern read vada rule
interpret roxadustat result suggest slight increas
risk overal vadadustat program achiev mace non-inferior
success see potenti favor read mace non-inferior
ndd-ckd program base differ control arm
increas concern around reach mace non-inferior ndd-ckd
program posit newly-onset ckd portion neg dialysi
depend esa convers portion overal see readthrough
increment will write akba
trial point due differ statist criteria/design
enrol criteria control arm fgen close mace non-inferior
miss potenti suggest increas mace risk aranesp control
arm trial may enabl vadadustat meet non-inferior statist
valu usd unless otherwis note
valu usd unless otherwis note
ebitda miss drive share lower concern around ramp center
report came sell-off ebitda miss guidanc
re-affirmed pipelin visibl remain low lower target
leav quarter street expect around guidanc low set
lower bar see upsid need see approv deal neither
near-term certain host dinner manag late-may
full-year guidanc re-affirmed overshadow
ebitda miss report ebitda million well street
million per first take link three primari driver miss
light brand sale driven higher rytari gross-to-net time zomig
shipment ii bp sequenti declin gener gross margin iii
higher expect sg spend driven one-off item three
start revers realiti impli ramp get mid-point
guidanc ebitda million got steeper updat
model ebitda estim move million million
million guidanc ebitda expect
could help push stock higher pipelin convert understand
back-end weight launch could deliv meaning ebitda ramp
first need see approv hit
post solid result revenu adj ebit come better
expect upsid come marketplac subscript
advertis revenu adj ebit guidanc rais wake
strong result fundament remain robust believ on-going busi
momentum help maintain premium growth reiter outperform
pt
solid rais outlook revenu reach ahead
rbc/street upsid come
marketplac subscript advertis adjust ebit
beat rbc/street due revenu upsid better expect
leverag cog revenu guid beat street adj ebit
guid came street higher occur align car
shop season revenu ebitda guid rais wake
strong result fundament trend consist robust
modest deceler revenu growth y/i vs
adjust ebit margin expand y/i record-high
steadi goe
valu usd unless otherwis note
valu usd unless otherwis note
report cfp miss consensu manag
hold firm activ plan expect recent improv oil
price provid solid uplift free cash flow gener leverag
reduct effort progress albeit slowli
report miss report cfp miss
our/consensu estim product kboe/d
consensu kboe/d
outlook get boost reiter product guidanc
kboe/d well capital-expenditure budget million chang
capit spend plan expect recent strength oil price
provid favor uplift free cash flow gener current strip
expect free cash flow million compar prior goal
million base oil
slowli progress leverag front remain activ
 front despit sale process take longer anticip regard
houston area land sale expect close addit million packag
later summer leverag front near term goal debt-to-
ebitdax draw closer manag expect leverag level
fall
cfp estim price reduc
upcom datapoint bridg data
timelin intact across pipelin includ lead cin program
set divers data point guid allow comfort look
ino overal platform across hpv-driven pre-canc io area nearer-
term focu turn ph i/ii interim data combo gbm year-end
granular expect mid-year believ new
data point value-driv program could refresh confid pipelin
provid sourc upsid adjust pt model updat
remain outperform specul risk rate
program interim ain/vin later year potenti whet appetit ahead
cin data manag continu pleas reveal trial
progress commit robust program updat mid-year
continu expect pivot data releas late success bla
file
data toward end year addit program help flesh
larger opportun io interim data fulli enrol pt
open-label ph i/ii newli diagnos gbm still store end
year lend inform look potenti t-cell
activ ahead os data fuller opportun gbm
bladder interim data ye also possibl account
valuat
recent data rare indic rrp spur compani enthusiasm potenti tack
opportun follow data set manag
shown new enthusiasm early-stag highlight asset
versatil orphan recurr respiratori papillomatosi rrp though
earli valuat
valu usd unless otherwis note
valu usd unless otherwis note
financi unev end quarter cash boost
recent net convert provid cash cushion
report post-clos brought higher expect eros
base busi partial overshadow otherwis good week
compani given posit droopi eye data monday share
fail reflect lower target revis estim near-term
biggest focu rvl prepar nda submiss
made sever model updat collect take price target
biggest chang pertain methylphendi gener concerta
lower estim follow year-over-year declin
sale sever addit gener competitor recent enter market
pressur price volum still hold also
lower estim non-promot revenu chang
partial off-set lower assum opex spend feedback launch ramp
osmolex er encourag product remain small
contributor point notic miss materi updat ontinua
er arbaclofen follow mix phase data earlier year
reaffirm confid overal dataset
see nerlynx miss vs st dash investor optim
strong reignit concern nerlynx sale may hit plateau
alreadi peak management detail rational return growth throughout
remaind see newli issu guidanc challeng creat
tough setup expect remaind year
see major nerlynx miss guidanc reduct call today
aftermarket report surprisingli poor nerlynx sale
well st bbg factset declin q/q despit
price hike januari investor call press releas slide
reduc nerlynx revenu guidanc prior
larg in-lin miss vs st management detail varieti
neg impact demand q/q revenu recognit q/q
detail model see turnaround q/q growth
releas impact see even new lower guidanc
challeng base model nerlynx shockingli poor dash
cautious optimist hope print-bas onscript trend link biotech
preview nerlynx track model updat reinvigor concern
patient discontinu may outstrip new start patient initi
stage launch begin complet therapyin-lin prior
mathemat model link got splain mathemat
model led pt reduct download nerlynx see growth slow
discontinu threaten trajectori updat financi model reflect
valu usd unless otherwis note
nerlynx sale slightli reduc guidanc vs guid
search new plan
headlin metric mix enterpris bill surpris
led reduc outlook addit investor find
familiar posit abrupt ceo departur interim head newli name
cfo follow earli sign enterpris strength last quarter thought
line-of-sight previou goal find soft disappoint
decreas pt
need know overal number mix vs expect
consensu enterpris secur revenu flat organ cc
miss consensu off-set consum cyber safeti revenu
flat organ cc slightli better vs consensu shortfal
es accompani declin bill found surpris
culprit includ poor commun around atp bundl proxysg
fall faster anticip reflect less refresh opportun
soft around cloud though product improv appar
result better posit outlook reduc es soft like
level achiev current trend like need
see out-performance get comfort estim
quarter accompani abrupt familiar ceo chang
greg clark step ceo richard hill take interim
presid ceo search underway full-tim ceo addit
vincent pilett cfo logitech appoint cfo overal found
result outlook disappoint manag chang frustrat
investor find familiar posit uncertainti await
new ceo could entail chang assess reset
expect maintain sp reduc target lower estim
newer oper continu improv along strength ss base
transit newly-acquir oper
supplement continu strength ss base drive anoth beat rais
carri last year momentum earli manag note
still consider runway left improv maintain op rais pt
base sum-of-th part analysi given pend spin-off
result continu demonstr embed organ growth
improv occup margin transit newly-acquir facil
coupl continu strength ss base
appear signific room upsid perform
exist oper ampl liquid grow pipelin expect
manag continu execut playbook grow
valu usd unless otherwis note
addit plan spin-off health hospic senior
live segment allow sharehold captur valu better posit
new public entiti separ growth opportun
post disappoint one senhanc sale guidanc
guidanc includ system sale rbce manag
continu expect greater system ramp vs
valu usd unless otherwis note
miss system sale guid report result
includ one senhanc sale vs guidanc sale rbce
vs fce one system sold end user taiwan total revenu
quarter rbce vs fce compar
regard guidanc manag anticip senhanc system
sale greater system ramp vs low end
guid seem achiev call manag state alreadi
receiv one senhanc purchas order expect receiv anoth
week
crucial year think compani see upsid share
manag prove senhanc us commerci viabil investor thu
far constrain unit state surgeon
fli europ observ live surgeri senhanc howev greater
number senhanc system place increas credenti
train surgeon commerci constraint may eas
lower revenu price target reduc
revenu increas y/i revenu
increas y/i lower senhanc sale
unit unit await visibl sign us commerci viabil lower
price target
post lower revenu ebitda came
street estim though true guid came expect
due continu organ traffic issu headwind oem partnership
lower estim maintain sector perform lower pt
host manag la june
 lower revenu y/i street
adjust ebitda margin also street
estim guidanc came street expect call
revenu vs street adjust
ebitda vs street overal fundament trend deterior
revenu growth deceler y/i vs ebitda margin
valu usd unless otherwis note
valu usd unless otherwis note
valu usd unless otherwis note
zg deliv result beat rbc/street revenu ebitda
out-performance segment though soft continu premier
agent segment outlook came street revenu bracket
ebitda high end tweak estim increas pt maintain sector
strong result outlook zillow post revenu
rbc/street upsid come larg home
busi ebitda margin came rbc/street
beat primarili driven account adjust one-off
item along discretionari expens control imt revenu came
line street all-import premier agent revenu tad
ahead consensu revenu guidanc well
street expect ebitda guidanc
bracket street segment deliv posit surpris
sold home nearli tripl sequenti trend core imt
segment remain soft seem stabil compani lift
lower end full-year imt guid
takeaway hr investor brief
new product acceler revenu growth electrophysiolog ep ep
smallest seven busi unit report revenu figur
plan seri product launch next month
fill remain gap ep portfolio manag believ replic
success achiev map navig portfolio futur ep product
emblem s-icd remain import growth driver within portfolio
emblem s-icd seventh year market remain growth mode
major market europ japan
number initi help sustain strong sale growth watchman
run nationwid direct-to-consum campaign watchman follow
promis result pilot ad program japan seek reimburs
watchman
manag meet highlight far good cobr panama
earli metric posit cobr panama
first concentr shipment expect june shipment could
earlier date allow presid panama attend
note confer call last week copper recoveri close
concentr grade expect reach
manag remain confid capit estim timelin
first quantum expect major chang polici recent elect
outgo presid remain offic month may tri resolv
market data cad financi data usd dividend paid
valu usd unless otherwis note
still uncertainti around zambia sale tax
last friday govern zambia releas list faq potenti
exempt propos sale tax expect come forc juli
first quantum estim result would increas group cost
aisc approxim per year thereaft
exclud cobr panama reduc navp ebitda
estim
first quantum review except see potenti reduc
tax bill howev stage unclear impact might
believ could increment posit relief full tax
like price
debt repay focu cobr panama
first quantum first prioriti follow ramp cobr panama repay
note road ndr eleph room
take-away host seri meet mid-atlant yesterday
humana ceo bruce broussard vice-president investor relat ami smith
meet focus compani busi segment especi
strategi growth prospect medicaid dual servic line
eventu question would turn news stori run week
/wcg deal interest make offer
manag would comment report remind
attende approach review major capit alloc decis
like histor context compani never realli done
larg transform transact instead develop growth
platform organ exercis increment option
opinion hum/cnc deal might meet criteria dont
believ meet last hurdl would never say never
probabl transact look low opinion dont
believ hum style go hostil
deal could interest realiti enterpris
well posit futur offer comprehens clinic care
manag payment model evolv medicar advantag opportun
long tailwind multipl opportun grow medicaid
takeaway hr investor meet
larg account repres signific growth opportun accord
manag own ambulatori cardiac monitor
valu usd unless otherwis note
valu usd unless otherwis note
market larg account repres market
current penetr tradit target physician
group small-to-mid size hospit develop relationship irtc
new busi strategi larg account address hospit concern
access time care increas patient satisfact oper effici
standard care grow patient volum cardiovascular
zio expect enter full commerci launch sinc zio
launch devic pull sale zio xt recal zio target
approxim legaci ecg market test per year
test per year compet directli mcot devic use
report structur order entri data repositori xt thu
fundament still intact continu believ one
innov growth compani med-tech believ compani
grow revenu y/i driven market expans increas sale
forc product howev investor reimburs continu
remain overhang stock await clariti
reimburs impact irtc code transit
categori temporari categori perman code
eps/cfp slight miss pivot scale develop
earn bit soft recur eps/cfp slightli
consensu estim miss
relat higher cash cost product mboe/d mb/d oil match
our/consensu mboe/d mb/d oil expect result
mid-point compani mboe/d mb/d oil guidanc rang
 capit spend million million forecast
million consensu expect
manag reiter product guidanc rang
mboe/d mb/d oil million budget inclus
aforement leasehold plan jag pivot quickli larger
howev provid stronger perform still hit spend
product guidanc well expect on-line
compar current well model product guidanc
mboe/d mbbl oil our/consensu mboe/d mb/d oil
manag re-work oper plan acceler larger develop
drill six well-pad coriand eight well-pad venom move
replac sever two-wel pad result less well on-line
think ultim outcom posit progress
effici scale develop scheme
result gener in-lin terp adjust ebitda
million larg line forecast million consensu
million overal gener long-term-averag europ
manag note strong wholesal market price off-set below-
averag resourc north american gener also impact
below-averag wind solar resourc avail
valu usd unless otherwis note
valu usd unless otherwis note
continu execut cost-sav initi north american wind
fleet success transfer project system control
function manag expect turn remain
site blade repair work complet expect juli
manag continu expect yield approxim million annual
execut letter intent purchas mw solar portfolio massachusett
portfolio consist four solar project oper
manag servic agreement sinc right first offer
seller million acquisit close two phase
first mw june remain mw decemb
confer call friday may et dial-in number
call expect investor focu addit
detail regard solar tuck-in futur opportun
commentari terp cost-sav initi
upsid revenue/ebitda rais outlook posit
well receiv assum mtw confid rais fy outlook
backlog slip y/i reflect strong bauma trade show occur earli
april like siphon order
outlook rais ebitda consensu
revenu
consensu
highlight ebitda expand y/i beat consensu
margin expand y/i top f/
edg
color note higher crane shipment america
euraf along better mix favor price commerci construct
energi end market sound good note soften y/i demand
euraf residenti commerci end market overal backlog
y/i q/q calcul new order would
y/i q/q
post-cal lusp submiss focu clinic catalyst
continu see clinic potenti luspatercept treatment anemia
beyond initi file indic low-risk md transfusion-depend beta-
thalassemia though remain cautiou neuromuscular franchis
myostatin target agent pre-clin data sotatercept pah
promis keep upsid model maintain pt sp rate
report financi result provid progress updat
hematolog neuromuscular pulmonari program along guidanc
clinic catalyst continu see luspatercept partner
celg primari valu driver recent submiss bla
treatment md beta thalassemia associ anemia us/
valu usd unless otherwis note
valu usd unless otherwis note
eu april previous guid approv expect april us
eu standard review process see note near term
focu remain readout part studi evalu
myostatin agent inhibitor tgf-b fshd facioscapulohumer muscular
dystrophi look evid function muscl
min walk test gait analysi upper limb perform test fshd health index
readout studi luspatercept inmyelofibrosi mf
view high-risk high-reward indic luspatercept xlrn day
pre-clin evid sotatercept pulmonari arteri hypertens pah
compel show reduct pulmonari arteri pressur pap
along reduct right ventricular hypertrophi management indic
reduct pap consid clinic meaning seer note
though keep indic upsid ahead clinic data maintain
pt sector perform rate
altair solid start year particular strength transit toward
softwar revenu combin adj-ebitda expect
guidanc maintain top-lin due part continu fx headwind
profit taken higher maintain sp rate pt
appreci evolv model feel valuat fair
need know altair deliv strong start upsid
metric specif non-gaap revenu y/i vs consensu
main focu busi improv mix
softwar revenu help drive upsid remain import
long-term profit core compani abil expand margin
acceler total revenu growth compani strong quarter
apac emea region posit given recent pmi trend
slow region america gain momentum focu
hire feel compani deliv solid start year guidanc
posit continu success maintain sp rate pt
appreci execut find valuat fair
model updat asthma data featur oral present eaaci
updat model financi corpor updat includ
plan present etokimab asthma data oral session eaaci
delay readout trial palmoplantar psoriasi
ppp updat model includ report maintain
pt sector perform spec risk rate
valu usd unless otherwis note
valu usd unless otherwis note
etokimab oral present schedul june eaaci expect
see granular detail asthma trial announc plan
present detail data trial etokimab eosinophil asthma
oral present european academi allergi clinic
immunolog congress recal announc present data
etokimab trial asthma septemb investor link
asthma top-lin result note link deep dive preview note eaaci
look detail around rang drug placebo respons
time point addit biomark data better understand etokimab
impact pathway eosinophil patient asthma
updat model account financi report maintain
pt sector perform rate
manag
spent time manag visit investor convers focus
chang go-to-market new product initi partnership
competit reiter sp pt
host manag investor meet discuss focus
chang go-to market partnership product innov
post all-around mix modest beat book ebitda
room night miss revenu ep rel street impli
stabil growth rate despit on-going macro fx headwind neither
less construct maintain outperform growth opportun biz
model valuat pt unchang
mix lower book larg in-lin street
benefit higher expect european room night march off-set
lower adr revenu came well consensu
mostli due high portion book late quarter ebitda
came slightli ahead street non-gaap ep
tad street guid book room night growth
ebitda ep came street due on-going euro macro worsen
fx headwind manag expect payment platform transit
modest neg impact ebitda growth vs prior expect
impact fundament trend modestli neg
impli growth rate stabil room night growth power
strong march result europ
valu usd unless otherwis note
valu cad unless otherwis note
cnq first-quart result reinforc confid abil gener
distributefre cash flow one thing wed like see better
defin market access strategi particularli oil export line delay
maintain outperform recommend cnq one-year price
target per share
result punctuat billion free cash flow dividend
million sharehold distribut dividend buyback driven
formula approach free cash flow distribut pace cnq buyback
acceler balanc peg cnq full-year share
repurchas billion
oper updat cnq tailor mainten activ optim
product connect alberta mandat curtail
plan turnaround scotford south upgrad commenc april limit
run-rat bbl/d net follow complet product
albian mine averag bbl/d net
remaind second-quart
result outlook larg expect manag remain bullish
integr effort trendkit falcon well abil expand
organ growth continu success overal remain upbeat around
opportun recent acquisit acceler organ growth rate
need know result larg expect manag remain
posit earli contribut integr effort trendkit
falcon past sever year compani done lot heavi
lift build out/integr earn media platform believ
point product deliv acceler growth
continu de-lev balanc sheet still think organ growth
potenti acceler year positive/st
macro trend adopt bundl sale strong push unifi
valu usd unless otherwis note
valu usd unless otherwis note
solid dropbox
post bracket result profit beat enu
integr still like cast n-t headwind margin
expand organ fundi much intact estim larg unch ed pt
solid ep result fundament trend larg consist
revenu growth slightli deceler y/i vs last op
inc margin sequenti y/i
arpu y/i came ahead rbc/street
est primarili driven strong adopt dbx premium profession
advanc plan new pay user paid user net add
hellosign ahead rbc/street estim consist
net add total pay user y/i increas
free dropbox gener ex/ one-tim item
margin manag expect gener
quarter decel q/q y/i tho margin remain near-term headwind
overlap expens hq buildout acquisit integr
consist revenu growth robust flow back margin expand
compani move past one-tim still
internet scalabl saa predict freemium model enabl
highli cost-effici custom acquisit high custom retent level
substanti revenu visibl plenti upsel opportun
continu see favor set stock given consist nnpu
strong arpu growth last sever quarter drive robust revenu
fundament growth trend go forward
valu usd unless otherwis note
valu usd unless otherwis note
invest activ picked-up improv
remain encourag long-term prospect believ share reflect
attract defens option uncertain macro environ earn
trend impact near-term headwind abat next
sever quarter therefor expect core earn growth acceler
rate target unchang
lower ffo estim
share respect also introduc
estim
compani complet million acquisit may
expect deploy anoth million
pro-forma net debt ebitda ratio current sit near
mid-point long-term rang
expect asset well posit gener organ growth
time near-term nois
overal solid quarter despit stock reaction guidanc re-affirmed expect
put solid re-affirmed guidanc mark notabl
consist compani hit target rel peer stock
respond may suffer group-wid neg read today
nevertheless leav quarter focu area unchang cch cellulit
bla file on-track ii opioid litig uncertainti chang
outlook
leav quarter estim larg unchang balanc
year solid beat larg driven steril inject
though segment in-lin street segment benefit
strong vasostrict volum favor impact time
shipment effect expect revers steril inject
segment lower million said see
continu strong execut year expect remain
reflect new product launch contribut ramp late
cch cellulit bla file on-track sever unknown focu
set pick-up expect low accept bla like add
confid price flexibl ie link xiaflex think
price clearli dictat appetit procedur per recent day
discuss clear enthusiasm around potenti product
view limit treatment option high unmet need could
drive strong patient interest right price
opioid litig remain primari overhang unsurprisingli visibl
continu limit still unclear whether part track
ohio mdl trial octob compani remain potenti settlement
discuss prepar trial unabl reach settlement
valu usd unless otherwis note
adjust ebitda ahead revenu guidanc unchang
report would consid rel decent quarter revenu
expect inclus fx headwind adjust
ebitda nice forecast manag expect revenu
flat q/q increas larg contract ramp
result exela report revenu forecast
adjust ebitda margin forecast
revenu lower expect inform transact
process itp versu forecast legal loss
prevent versu forecast healthcar
versu forecast
growth larg client believ continu take wallet share
largest client year-end client
annual revenu year-end level
client gener annual revenu compani disclos
total annual contract valu acv ramp
fulli ramp quarter end rest later year
maintain ebitda estim target price incorpor result
guidanc maintain adjust ebitda estim
respect increas adjust ep estim
ep estim reflect
lower run-rat level unchang forward adjust ebitda
estim maintain target price ev/ebitda multipl
rbce multipl base case valuat discount
direct peer lack combin financi histori xela higher
peer leverag
although ngp provid addit sourc revenu growth imperi brand
think erod profit tobacco industri updat
forecast post result currenc move price target unchang
retain under-perform rate
updat model currenc move result apv-deriv price
target remain unchang keep under-perform rate
market data gbp financi data gbp dividend paid
post-cal edelweiss get underway implant data
expect ye
obsv provid updat develop progress includ initi
registr edelweiss trial endometriosi reiter two
key enrol complet catalyst schedul implant primros
updat model account report maintain pt
outperform rate
valu usd unless otherwis note
valu usd unless otherwis note
obsv report result morn announc initi
edelweiss trial reiter timelin multipl late-stag catalyst
across develop pipelin throughout notabl
obsv expect provid updat meet fda
discuss nolasiban protocol design complet enrol
implant primros nolasiban linzagolix respect
readout top-lin data implant primros
primros
share compani updat earli launch revenu
million slightli consensu investor focu remain report
prescript growth gaug launch trajectori growth
sequenti robust slow growth latest week
period overal leav quarter view intact chang outlook
focu go remain higher prescript growth latest
period still good also reflect slow compar
increas intranas steroid market time frame
april number yet period end
show month-over-month growth also indic iqvia
captur overal script averag revenu per prescript came
slightli guid slight stock benefit also
seen manag reiter expect rang
perspect take current consensu net price impli month
month growth need hit consensu current
recent sale forc chang expect drive greater growth
expans territori dtc pilot also kick near-term transit
intern sale forc previous contract also increas
sale territori addit physician previous
untarget remain unclear whether xhanc experi
season seen last year march-may peak season mid-jun
august trough given differ dynam year
new patient afford program higher mix refil sampl
manag indic may earli understand whether
season could promin year continu expect
valu usd unless otherwis note
market data usd financi data eur dividend paid
strategi detail ep re-set execut valuat debat
manag pleas reaction today outlook re-
set strategi growth detail surpris reaction
back mix result lower remain-co outlook expect
path detail come sever built-in opportun boost annual ep
growth execut need factor remain
think number ye signific
dis-synergi appropri cautiou anticip
outlook matter stock come mix last night link
ep rang includ rx street
call rx impact remov busi
estim includ ep add-back debt reduct assum
billion take pro-forma ep link
includ reinvest proce put price-to-earnings
midpoint within consum multipl initi thought
valuat give credit heavi lift execut yet
happen manag two thing think help point margin
ramp rebas level toward medium term basi point
add ep ii left ranir acquisit gener proair
save add ep support reflect built-in cushion
model updat focu usher syndrom data post-rdeb program spin-
like increas resourc alloc ophthalmolog diseas franchis
recent rdeb spin-out see upcom usher syndrom data
somewhat de-risk data despit challeng
endpoints/design continu
like prqr unappreci rna
ophthalmolog platform maintain pt op spec risk rate
prqr releas financi result oper updat upcom
clinic catalyst continu focu earli clinic data usher
syndrom prqr report result highlight
progress key clinic program
usher syndrom type announc spin-out deb newli
form wing maintain minor stake upcom catalyst
studi evalu sepofarsen patient dose
first patient april near-term focu remain updat
stellar studi exon mutat usher syndrom type
clinic data expect optimist molecular
improv seen translat usher syndrom given similar
mutat target oligonucleotid cilium retin photo-receptor
sepofarsen predominantli target cone primarili target rod
posit preclin data anim model organoid
road manag
spent two day road boston/nyc ceo andr reiner
vice-president control scott cook takeaway follow
spent time manag meet investor discuss focus
manag convict growth market structur competit chang
area innov profit capit alloc
market data usd financi data usd dividend paid
valu usd unless otherwis note
move annual guidanc signifi strategi shift recur iot servic
sierra report slightli street expect compani provid
guidanc instead re-affirmed prior revenu adj ebitda
outlook shift quarterli annual guidanc reduc short-term
investor visibl may help reduc volatil stock around quarter long-
term valuat re-rat depend faster iot servic growth
remain seen
result slightli better expect revenu declin y/i
slightli rbc/street near high-end
guidanc result slightli higher revenu lower opex
adj ebitda y/i street
adj ep rbc/street high-end
guidanc
shift away quarterli guidanc sierra provid quarterli guidanc
instead re-affirmed prior guidanc flat revenu growth
revenu adj ebitda compani guid
adj ep slightli previous follow revenu
estim unchang adj ep estim move
previous
messag re-align iot servic stori concurr shift annual
guidanc sierra revis revenu segment provid better investor
visibl growth iot solut servic variabl embed
valu cad unless otherwis note
valu cad unless otherwis note
broadband automot pc oem sierra target total revenu
next year iot servic impli doubl iot servic
run-rat
balanc still deliv promis
one-tim credit event asid underli result solid thesi track
maintain price target outperform rate
view underli ep exclud one-off neg credit impact
better estim consensu exclud
credit impact asia result line expect major
segment better forecast
asia underli earn exclud one-off credit impact
million rel line estim individu life insur sale
yoy constant fx reflect double-digit growth asian market
intern insur sale continu declin
mf report net outflow billion improv last quarter
better expect mutual fund experienc net inflow
billion vs billion outflow last quarter howev institut fund
remain net outflow billion
slf total licat ratio opco holdco increas qoq
respect slf increas dividend per share intend
increas share buy-back program million share
price target remain unchang maintain outperform
rate underli ep estim larg unchang
valuat gener peer think deserv given similar
return expect lower risk profil slf trade
underli ep estim compar peer averag stock trade
histor averag premium peer consensu forward p/
